Medicare Part D
-
Prediction: MA is the new PBM (Part D, III)
Read more: Prediction: MA is the new PBM (Part D, III)I’d like to make a prediction. The next big political focus (after PBMs, if we give up on PBMs?) is going to Medicare Advantage. There is a lot of money flowing through managed care and scrutiny feels inevitable. It is just that if you’re following the dollar, a lot is going that way. A few…
-
Caught my eye — 10/20/23
Read more: Caught my eye — 10/20/23Want a friend, get a cat. A doctor prescribes a cat for a patient. I question the out-of-pocket costs of the Rx, but point taken. Speaking of PETS. A few Alzheimer’s updates – Déjà vu. The Part B premiums increased in 2024 due to newly approved Alzheimer’s treatments. It wasn’t noted in the fact sheet…
-
They don’t build them like they used to. For Part D, it’s better (Part 2)
Read more: They don’t build them like they used to. For Part D, it’s better (Part 2)Recently my treadmill became a paperweight. The technician came out and said that it would be better to buy the parts and fix it because the new ones were just not made as well as my old one. A refrain I’ve heard over the years as it relates to heating units, refrigerators, etc. But Part…
-
Part D Evolution, Part 1: Enrollment
Read more: Part D Evolution, Part 1: EnrollmentThis time of year brings on a sense of nostalgia for me related to the Medicare prescription drug benefit (Part D). Back in 2005, I had just started working at Avalere and we got our first data on what plans were offering for the inaugural year of the benefit. I remember launching into the file…
Latest news
- Caught my eye — 03/28/25
- Caught my eye — 3/21/25
- Caught my eye — 3/14/25
- Caught my eye — 03/07/25
- Caught my eye — 2/28/25
Categories
- 340B (33)
- Affordable Care Act (4)
- Alzheimer's (5)
- Biosimilars (20)
- Caught my eye (61)
- Cell and Gene (1)
- Chevron Deference (2)
- CMMI (10)
- Copay Accumulators (6)
- COVID (2)
- Drug Prices (30)
- Drug shortages (8)
- DTC (2)
- Employers (7)
- Generics (5)
- Health Equity (3)
- Healthcare Costs (28)
- ICER (9)
- Importation (2)
- Inflation Reduction Act (45)
- Insulin (4)
- IP (3)
- Long term care (1)
- Medicaid (6)
- Medicare Advantage (15)
- Medicare Negotiation (48)
- Medicare Part D (44)
- Medicare Transaction Facilitator (2)
- Medicare Transaction Facilitator (7)
- Obesity (20)
- On the Horizon (1)
- Orphan Drugs (3)
- Pharmacy Benefit Managers (28)
- Reference Pricing (5)
- State-based Reform (14)
- Supply Chain (1)
- Uncategorized (4)
- Utilization Management (1)
- Vaccines (4)
- Value (12)